BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 30984874)

  • 1. Galantamine-memantine combination superior to donepezil-memantine combination in Alzheimer's disease: critical dissection with an emphasis on kynurenic acid and mismatch negativity.
    Koola MM; Nikiforuk A; Pillai A; Parsaik AK
    J Geriatr Care Res; 2018; 5(2):57-67. PubMed ID: 30984874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Galantamine-Memantine Combination for Cognitive Impairments Due to Electroconvulsive Therapy, Traumatic Brain Injury, and Neurologic and Psychiatric Disorders: Kynurenic Acid and Mismatch Negativity Target Engagement.
    Koola MM
    Prim Care Companion CNS Disord; 2018 Mar; 20(2):. PubMed ID: 29570959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential Role of Antipsychotic-Galantamine-Memantine Combination in the Treatment of Positive, Cognitive, and Negative Symptoms of Schizophrenia.
    Koola MM
    Mol Neuropsychiatry; 2018 Dec; 4(3):134-148. PubMed ID: 30643787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Galantamine-Memantine combination in the treatment of Alzheimer's disease and beyond.
    Koola MM
    Psychiatry Res; 2020 Nov; 293():113409. PubMed ID: 32829072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Galantamine-Memantine Combination and Kynurenine Pathway Enzyme Inhibitors in the Treatment of Neuropsychiatric Disorders.
    Bai MY; Lovejoy DB; Guillemin GJ; Kozak R; Stone TW; Koola MM
    Complex Psychiatry; 2021 Aug; 7(1-2):19-33. PubMed ID: 35141700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attenuated Mismatch Negativity in Attenuated Psychosis Syndrome Predicts Psychosis: Can Galantamine-Memantine Combination Prevent Psychosis?
    Koola MM
    Mol Neuropsychiatry; 2018 Oct; 4(2):71-74. PubMed ID: 30397594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kynurenine pathway and cognitive impairments in schizophrenia: Pharmacogenetics of galantamine and memantine.
    Koola MM
    Schizophr Res Cogn; 2016 Jun; 4():4-9. PubMed ID: 27069875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical investigation of the functional effects of memantine and memantine combined with galantamine or donepezil.
    Woodruff-Pak DS; Tobia MJ; Jiao X; Beck KD; Servatius RJ
    Neuropsychopharmacology; 2007 Jun; 32(6):1284-94. PubMed ID: 17119537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential role of the combination of galantamine and memantine to improve cognition in schizophrenia.
    Koola MM; Buchanan RW; Pillai A; Aitchison KJ; Weinberger DR; Aaronson ST; Dickerson FB
    Schizophr Res; 2014 Aug; 157(1-3):84-9. PubMed ID: 24878431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The combination of memantine and galantamine improves cognition in rats: The synergistic role of the α7 nicotinic acetylcholine and NMDA receptors.
    Nikiforuk A; Potasiewicz A; Kos T; Popik P
    Behav Brain Res; 2016 Oct; 313():214-218. PubMed ID: 27435422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
    Bond M; Rogers G; Peters J; Anderson R; Hoyle M; Miners A; Moxham T; Davis S; Thokala P; Wailoo A; Jeffreys M; Hyde C
    Health Technol Assess; 2012; 16(21):1-470. PubMed ID: 22541366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.
    Loveman E; Green C; Kirby J; Takeda A; Picot J; Payne E; Clegg A
    Health Technol Assess; 2006 Jan; 10(1):iii-iv, ix-xi, 1-160. PubMed ID: 16409879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ginkgo biloba Extract (EGb761), Cholinesterase Inhibitors, and Memantine for the Treatment of Mild-to-Moderate Alzheimer's Disease: A Network Meta-Analysis.
    Thancharoen O; Limwattananon C; Waleekhachonloet O; Rattanachotphanit T; Limwattananon P; Limpawattana P
    Drugs Aging; 2019 May; 36(5):435-452. PubMed ID: 30937879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinically meaningful treatment responses after switching to galantamine and with addition of memantine in patients with Alzheimer's disease receiving donepezil.
    Kano O; Ito H; Takazawa T; Kawase Y; Murata K; Iwamoto K; Nagaoka T; Hirayama T; Miura K; Nagata R; Kiyozuka T; Aoyagi J; Sato R; Eguchi T; Ikeda K; Iwasaki Y
    Neuropsychiatr Dis Treat; 2013; 9():259-65. PubMed ID: 23431041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positive allosteric modulators of alpha 7 nicotinic acetylcholine receptors enhance procognitive effects of conventional anti-Alzheimer drugs in scopolamine-treated rats.
    Potasiewicz A; Krawczyk M; Gzielo K; Popik P; Nikiforuk A
    Behav Brain Res; 2020 May; 385():112547. PubMed ID: 32087183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Effectiveness and Safety of Cognitive Enhancers for Treating Alzheimer's Disease: Systematic Review and Network Metaanalysis.
    Tricco AC; Ashoor HM; Soobiah C; Rios P; Veroniki AA; Hamid JS; Ivory JD; Khan PA; Yazdi F; Ghassemi M; Blondal E; Ho JM; Ng CH; Hemmelgarn B; Majumdar SR; Perrier L; Straus SE
    J Am Geriatr Soc; 2018 Jan; 66(1):170-178. PubMed ID: 29131306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination Therapy of Cholinesterase Inhibitor (Donepezil or Galantamine) plus Memantine in the Okayama Memantine Study.
    Matsuzono K; Hishikawa N; Ohta Y; Yamashita T; Deguchi K; Nakano Y; Abe K
    J Alzheimers Dis; 2015; 45(3):771-80. PubMed ID: 25624417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
    Tan CC; Yu JT; Wang HF; Tan MS; Meng XF; Wang C; Jiang T; Zhu XC; Tan L
    J Alzheimers Dis; 2014; 41(2):615-31. PubMed ID: 24662102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current Practices in the Treatment of Alzheimer Disease: Where is the Evidence After the Phase III Trials?
    Ehret MJ; Chamberlin KW
    Clin Ther; 2015 Aug; 37(8):1604-16. PubMed ID: 26122885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease.
    Grossberg GT; Edwards KR; Zhao Q
    J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):17S-26S. PubMed ID: 16809811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.